Skip to main content
SpringerLink
Log in

Medical Therapy of HCC

  • Chapter
  • First Online:
Book cover Hepatocellular Carcinoma

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

The principles underlying medical management of HCC are based on an understanding of the clinical setting, the tumor characteristics, and the underlying biology. Reviewing our patient population, we found that 81 % of patients had cirrhosis and 19 % had no evidence of cirrhosis by biopsy or CT scan.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bartlett D, Marsh W, Carr BI. Hepatocellular carcinoma. In: DeVita et al., editor. Principles and practice of oncology. 7th ed. Philadelphia: Lippincott; 2004.

    Google Scholar 

  2. Dodd GD 3rd, Carr BI. Percutaneous biopsy of portal vein thrombus: a new staging technique for hepatocellular carcinoma. AJR Am J Roentgenol. 1993;161:229–33.

    Article  PubMed  Google Scholar 

  3. Dusenbery D, Dodd GD 3rd, Carr BI. Percutaneous fine-needle aspiration of portal vein thrombi as a staging technique for hepatocellular carcinoma. Cytologic findings of 46 patients. Cancer. 1995;75:2057–62.

    Article  CAS  PubMed  Google Scholar 

  4. Haddow A. Cellular inhibition and origin of cancer. Acta Unio Int Contra Cancrum. 1938;3:342–52.

    Google Scholar 

  5. MacNider W. A study of the acquired resistance of fixed tissue cells morphologically altered through process of repair. II. The resistance of liver epithelium altered morphologically as a result of an injury from uranium, followed by repair to the hepatotoxic action of chloroform. J Pharm Exp Ther 1936;56:373–82.

    Google Scholar 

  6. Solt D, Farber E. New principle for the analysis of chemical carcinogenesis Nature. 1976;263:701–3.

    CAS  Google Scholar 

  7. Carr BI, Laishes BA. Carcinogen-induced drug resistance in rat hepatocytes. Cancer Res. 1981;41:1715–9.

    CAS  PubMed  Google Scholar 

  8. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.

    Article  CAS  PubMed  Google Scholar 

  9. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.

    Article  PubMed  Google Scholar 

  10. Carr B. Escalating cisplatin doses by intrahepatic infusion for advanced stage hepatocellular carcinoma. Proc ASCO. 1996;15:23.

    Google Scholar 

  11. Carr BI, Dvorchik I. Effects of cisplatin dose intensity on response and survival for patients with unresectable and untransplantable hepatocellular carcinoma: an analysis of 57 patients. Gan To Kagaku Ryoho. 2000;27(Suppl 2):432–5.

    PubMed  Google Scholar 

  12. Amesur NB, Zajko AB, Carr BI. Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles. Dig Dis Sci. 2008;53:1400–4.

    Article  PubMed  Google Scholar 

  13. Carr B, Selby R, Madariaga J, et al. A controlled, prospective randomized trial comparing intra-arterial cisplatin and doxorubicin with or without Lipiodol for hepatocellular carcinoma. Hepatology. 1992;16:60.

    Article  Google Scholar 

  14. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6–25.

    Article  PubMed  Google Scholar 

  15. Ebied OM, Federle MP, Carr BI, et al. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2003;97:1042–50.

    Article  PubMed  Google Scholar 

  16. Katyal S, Oliver JH, Peterson MS, Chang PJ, Baron RL, Carr BI. Prognostic significance of arterial phase CT for prediction of response to transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: a retrospective analysis. AJR Am J Roentgenol. 2000;175:1665–72.

    Article  CAS  PubMed  Google Scholar 

  17. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. Nwe Engl J. Med. 2008;259:378–90.

    Article  Google Scholar 

  18. Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol. 2015;7:2009–19.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.

    Article  PubMed  Google Scholar 

  20. Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:920–5.

    Article  CAS  PubMed  Google Scholar 

  21. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:1532–8.

    Article  CAS  PubMed  Google Scholar 

  22. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

    Article  CAS  PubMed  Google Scholar 

  23. Lencioni R, Kudo M, Ye SL, et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract. 2012;66:675–83.

    Article  CAS  PubMed  Google Scholar 

  24. Liebman HA, Furie BC, Tong MJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310:1427–31.

    Article  CAS  PubMed  Google Scholar 

  25. Carr BI, Wang Z, Kar S. K vitamins, PTP antagonism, and cell growth arrest. J Cell Physiol. 2002;193:263–74.

    Article  CAS  PubMed  Google Scholar 

  26. Nakao A, Virji A, Iwaki Y, Carr B, Iwatsuki S, Starzl E. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma. Hepatogastroenterology. 1991;38:450–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Habu D, Shiomi S, Tamori A, et al. Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA. 2004;292:358–61.

    Article  CAS  PubMed  Google Scholar 

  28. Kakizaki S, Sohara N, Sato K, et al. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection. J Gastroenterol Hepatol. 2007;22:518–22.

    Article  CAS  PubMed  Google Scholar 

  29. Mizuta T, Ozaki I, Eguchi Y, et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer. 2006;106:867–72.

    Article  CAS  PubMed  Google Scholar 

  30. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl. 2004;10:S107–10.

    Article  PubMed  Google Scholar 

  31. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116:1305–14.

    Google Scholar 

  32. Lai CL, et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer. 1989;60(6):928–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Lai CL, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology. 1993;17(3):389–94.

    Article  CAS  PubMed  Google Scholar 

  34. Llovet JM, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000;31(1):54–8.

    Article  CAS  PubMed  Google Scholar 

  35. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

    Article  CAS  PubMed  Google Scholar 

  36. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: unique challenges and clinical opportunities. Oncoimmunology. 2012;1(1):48–55.

    Article  PubMed  PubMed Central  Google Scholar 

  37. El-Khoueiry AB, Melero I, Crocenzi TS, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol. 2015 (suppl; abstr LBA101).

    Google Scholar 

  38. Boige V, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17(8):1063–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Thomas MB, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009;27(6):843–50.

    Article  CAS  PubMed  Google Scholar 

  40. Hsu CH, et al. Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study. Oncology. 2013;85(1):44–52.

    Article  CAS  PubMed  Google Scholar 

  41. Yau T, et al. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs. 2012;30(6):2384–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Knox JJ, et al. A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015;33(1):241–6.

    Article  CAS  PubMed  Google Scholar 

  43. Hsu CH, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010;102(6):981–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Zhu AX, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(12):1898–903.

    Article  CAS  PubMed  Google Scholar 

  45. XXX.

    Google Scholar 

  46. Zhu AX, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013;19(23):6614–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Zhu AX, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015;16(7):859–70.

    Article  CAS  PubMed  Google Scholar 

  48. Asnacios A, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer. 2008;112(12):2733–9.

    Article  CAS  PubMed  Google Scholar 

  49. Gish RG, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007;25(21):3069–75.

    Article  CAS  PubMed  Google Scholar 

  50. Dobbs NA, et al. Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. Cancer Chemother Pharmacol. 1994;34(5):405–10.

    Article  CAS  PubMed  Google Scholar 

  51. Hochster HS, et al. 4′Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol. 1985;3(11):1535–40.

    CAS  PubMed  Google Scholar 

  52. Halm U, et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol. 2000;11(1):113–4.

    Article  CAS  PubMed  Google Scholar 

  53. Lai KH, et al. Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemother Pharmacol. 1989;23(1):54–6.

    Article  CAS  PubMed  Google Scholar 

  54. Lee J, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol. 2004;54(5):385–90.

    Article  CAS  PubMed  Google Scholar 

  55. Shim JH, et al. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol. 2009;63(3):459–67.

    Article  CAS  PubMed  Google Scholar 

  56. Lee JO, et al. Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol. 2009;20(8):1402–7.

    Article  CAS  PubMed  Google Scholar 

  57. Boige V, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer. 2007;97(7):862–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Qin S, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013;31(28):3501–8.

    Article  CAS  PubMed  Google Scholar 

  59. Parikh PM, et al. A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol. 2005;26(3):115–8.

    CAS  PubMed  Google Scholar 

  60. Lombardi G, et al. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer. 2011;117(1):125–33.

    Article  CAS  PubMed  Google Scholar 

  61. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer. 2007;109:1384–90.

    Article  CAS  PubMed  Google Scholar 

  62. Zaanan A, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol. 2013;58(1):81–8.

    Article  CAS  PubMed  Google Scholar 

  63. Yeo W, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97(20):1532–8.

    Article  CAS  PubMed  Google Scholar 

  64. Kaseb AO, et al. Modified cisplatin/interferon alpha-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. Cancer. 2013;119(18):3334–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Couto OF, Dvorchik I, Carr BI. Causes of death in patients with unresectable hepatocellular carcinoma. Dig Dis Sci. 2007;52:3285–9.

    Article  CAS  PubMed  Google Scholar 

  66. Thomas MB. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). In: ASCO annual meeting, 2007.

    Google Scholar 

  67. Carr BI, Irish W, Federle MP. Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis. Hepatogastroenterology. 2010;57:1375–81.

    PubMed  Google Scholar 

  68. Carr BI, Bron K, Swanson DP. Prospective randomized trial of hepatic artery chemotherapy with cisplatin and doxorubicin, with or without lipiodol in the treatment of advanced stage hepatocellular carcinoma. J Clin Gastroenterol. 2011;45(9):e87–91.

    Google Scholar 

  69. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116:1305–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71–81.

    Article  PubMed  Google Scholar 

  71. Yoon SM, Lim YS, Park MJ, et al. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS ONE. 2013;8:e79854.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Kim DY, Park W, Lim DH, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer. 2005;103:2419–26.

    Article  PubMed  Google Scholar 

  73. Edeline J, Crouzet L, Campillo-Gimenez B et al. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging. 2015 Oct 12 (Epub ahead of print).

    Google Scholar 

  74. Korean Liver Cancer Study Group (KLCSG), National Cancer Center, Korea (NCC). 2014 KLCSG-NCC Korea practice guideline for the management of Hepatocellular Carcinoma. Gut Liver 2015;9(3):267–317.

    Google Scholar 

  75. Kudo M, Kitano M, Sakurai T, Nishida N. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan. Dig Dis. 2015;33:765–70.

    Article  PubMed  Google Scholar 

  76. Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol. 2015;7:673–87.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Kokudo N, Hasegawa K, Akahane M et al. Evidence-based clinical practice guidelines for Hepatocellular Carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC guidelines). Hepatol Res. 2015;45(2). doi:10.1111/hepr.12464.

    Google Scholar 

  78. Sciarrino E, Simonetti RG, Le Moli S, Pagliaro L. Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients. Cancer. 1985;56:2751–5.

    Article  CAS  PubMed  Google Scholar 

  79. Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep. 1984;68:487–91.

    CAS  PubMed  Google Scholar 

  80. Ihde DC, Kane RC, Cohen MH, McIntire KR, Minna JD. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treat Rep. 1977;61:1385–7.

    CAS  PubMed  Google Scholar 

  81. Falkson G, MacIntyre JM, Moertel CG, Johnson LA, Scherman RC. Primary liver cancer. An Eastern Cooperative Oncology Group Trial. Cancer. 1984;54:970–7.

    Article  CAS  PubMed  Google Scholar 

  82. Falkson G, MacIntyre JM, Schutt AJ, et al. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol. 1984;2:581–4.

    CAS  PubMed  Google Scholar 

  83. Ravry MJ, Omura GA, Bartolucci AA. Phase II evaluation of doxorubicin plus bleomycin in hepatocellular carcinoma: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1984;68:1517–8.

    CAS  PubMed  Google Scholar 

  84. Cavalli F, Rozencweig M, Renard J, Goldhirsch A, Hansen HH. Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol. 1981;17:1079–82.

    Article  CAS  PubMed  Google Scholar 

  85. Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer. 1983;51:206–10.

    Article  CAS  PubMed  Google Scholar 

  86. Melia WM, Westaby D, Williams R. Diamminodichloride platinum (cis-platinum) in the treatment of hepatocellular carcinoma. Clin Oncol. 1981;7:275–80.

    CAS  PubMed  Google Scholar 

  87. Ravry MJ, Omura GA, Bartolucci AA, Einhorn L, Kramer B, Davila E. Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986;70:311–2.

    CAS  PubMed  Google Scholar 

  88. Falkson G, Ryan LM, Johnson LA, et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer. 1987;60:2141–5.

    Article  CAS  PubMed  Google Scholar 

  89. Colleoni M, Buzzoni R, Bajetta E, et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer. 1993;72:3196–201.

    Article  CAS  PubMed  Google Scholar 

  90. Chao Y, Chan WK, Birkhofer MJ, et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer. 1998;78:34–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003;21:421–7.

    Article  CAS  PubMed  Google Scholar 

  92. Patt YZ, Hoque A, Roh M, et al. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. Am J Clin Oncol. 1999;22:209–13.

    Article  CAS  PubMed  Google Scholar 

  93. Bobbio-Pallavicini E, Porta C, Moroni M, et al. Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer. 1997;33:1784–8.

    Article  CAS  PubMed  Google Scholar 

  94. Okada S, Okusaka T, Ueno H, et al. Phase II trial of cisplatin, mitroxantrone and continuous infusion 5-fluorouracil for hepatocellular carcinoma. Proc ASCO. 1999;18:248A.

    Google Scholar 

  95. Guan Z, Wang Y, Maoleekoonpairoj S, et al. Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma. Br J Cancer. 2003;89:1865–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Taieb J, Bonyhay L, Golli L, et al. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer. 2003;98:2664–70.

    Article  CAS  PubMed  Google Scholar 

  97. Lee J, Park JO, Kim WS, et al. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. Cancer Chemother Pharmacol. 2004;54:385–90.

    Article  CAS  PubMed  Google Scholar 

  98. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer. 2005;103:756–62.

    Article  CAS  PubMed  Google Scholar 

  99. Zhu AX, Fuchs CS, Clark JW, et al. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005;10:392–8.

    Article  CAS  PubMed  Google Scholar 

  100. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:1898–903.

    Article  CAS  PubMed  Google Scholar 

  101. Kim SJ, Seo HY, Choi JG, et al. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2006;57:436–42.

    Article  CAS  PubMed  Google Scholar 

  102. Park SH, Lee Y, Han SH, et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer. 2006;6:3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  103. Li S, Niu Z, Tian H, et al. Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin. Hepatogastroenterology. 2007;54:218–23.

    CAS  PubMed  Google Scholar 

  104. Uhm JE, Park JO, Lee J, et al. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol. 2008;23:23.

    Google Scholar 

  105. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer. 2008;112:2733–9.

    Article  CAS  PubMed  Google Scholar 

  106. Koda M, Murawaki Y, Mitsuda A, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer. 2001;92:1516–24.

    Article  CAS  PubMed  Google Scholar 

  107. Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol. 2001;28:514–20.

    Article  CAS  PubMed  Google Scholar 

  108. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.

    Article  CAS  PubMed  Google Scholar 

  109. Martin RC, 2nd, Jarnagin WR. Randomized clinical trials in hepatocellular carcinoma and biliary cancer. Surg Oncol Clin N Am 2002;11:193–205.

    Google Scholar 

  110. Mathurin P, Rixe O, Carbonell N, et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma—an impossible meta-analysis? Aliment Pharmacol Ther. 1998;12:111–26.

    Article  CAS  PubMed  Google Scholar 

  111. Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs. 2004;15:439–52.

    Article  CAS  PubMed  Google Scholar 

  112. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol. 1997;8:117–36.

    Article  CAS  PubMed  Google Scholar 

  113. Thomas MB, O’Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol. 2008;15:1008–14.

    Article  PubMed  Google Scholar 

  114. Sasaki Y, Imaoka S, Kasugai H, et al. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer. 1987;60:1194–203.

    Article  CAS  PubMed  Google Scholar 

  115. Kasugai H, Kojima J, Tatsuta M, et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology. 1989;97:965–71.

    Article  CAS  PubMed  Google Scholar 

  116. Ohnishi K, Tsuchiya S, Nakayama T, et al. Arterial chemoembolization of hepatocellular carcinoma with mitomycin C microcapsules. Radiology. 1984;152:51–5.

    Article  CAS  PubMed  Google Scholar 

  117. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma—a randomized controlled trial. Gastroenterology. 1988;94:453–6.

    Article  CAS  PubMed  Google Scholar 

  118. Fujimoto S, Miyazaki M, Endoh F, Takahashi O, Okui K, Morimoto Y. Biodegradable mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. With particular reference to a comparison with continuous infusion of mitomycin C and 5-fluorouracil. Cancer. 1985;56:2404–10.

    Article  CAS  PubMed  Google Scholar 

  119. Audisio RA, Doci R, Mazzaferro V, et al. Hepatic arterial embolization with microencapsulated mitomycin C for unresectable hepatocellular carcinoma in cirrhosis. Cancer. 1990;66:228–36.

    Article  CAS  PubMed  Google Scholar 

  120. Kobayashi H, Hidaka H, Kajiya Y, et al. Treatment of hepatocellular carcinoma by transarterial injection of anticancer agents in iodized oil suspension or of radioactive iodized oil solution. Acta Radiol Diagn (Stockh). 1986;27:139–47.

    CAS  Google Scholar 

  121. Kanematsu T, Furuta T, Takenaka K, et al. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology. 1989;10:98–102.

    Article  CAS  PubMed  Google Scholar 

  122. Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M. Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer. 1989;64:1586–94.

    Article  CAS  PubMed  Google Scholar 

  123. Konno T, Maeda H, Iwai K, et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol. 1983;19:1053–65.

    Article  CAS  PubMed  Google Scholar 

  124. Pelletier G, Roche A, Ink O, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990;11:181–4.

    Article  CAS  PubMed  Google Scholar 

  125. Carr B, Starzl T, Iwatsuki S, et al. Aggressive treatment for advanced hepatocellular carcinoma (HCC): high response rates and prolonged survival. Hepatology. 1991;14:243.

    Google Scholar 

  126. Venook AP, Stagg RJ, Lewis BJ, et al. Chemoembolization for hepatocellular carcinoma. J Clin Oncol. 1990;8:1108–14.

    CAS  PubMed  Google Scholar 

  127. Ohnishi K, Sugita S, Nomura F, Iida S, Tanabe Y. Arterial chemoembolization with mitomycin C microcapsules followed by transcatheter hepatic artery embolization for hepatocellular carcinoma. Am J Gastroenterol. 1987;82:876–9.

    CAS  PubMed  Google Scholar 

  128. Beppu T, Ohara C, Yamaguchi Y, et al. A new approach to chemoembolization for unresectable hepatocellular carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil. Cancer. 1991;68:2555–60.

    Article  CAS  PubMed  Google Scholar 

  129. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med 1995;332:1256–61.

    Google Scholar 

  130. Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer. 1994;74:2449–53.

    Article  CAS  PubMed  Google Scholar 

  131. Stuart K, Stokes K, Jenkins R, Trey C, Clouse M. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer. 1993;72:3202–9.

    Article  CAS  PubMed  Google Scholar 

  132. Bruix J, Castells A, Montanya X, et al. Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology. 1994;20:643–50.

    Article  CAS  PubMed  Google Scholar 

  133. Carr BI, Zajko A, Bron K, Orons P, Sammon J, Baron R. Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced-stage hepatocellular carcinoma: interim analysis. Semin Oncol 1997;24:S6-97–9.

    Google Scholar 

  134. Carr BI, Zajko A, Bron K, et al. Prospective randomized study of intrahepatic artery chemotherapy with cisplatin and doxorubin, with or without Lipiodol in the treatment of advanced-stage hepatocellular carcinoma. Proc Am Soc Clin Oncol. 1993;12:668.

    Google Scholar 

  135. Carr BI. Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients. Hepatogastroenterology. 2002;49:79–86.

    CAS  PubMed  Google Scholar 

  136. Ngan H, Lai CL, Fan ST, Lai EC, Yuen WK, Tso WK. Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam. Clin Radiol. 1993;47:315–20.

    Article  CAS  PubMed  Google Scholar 

  137. Yamamoto M, Iizuka H, Fujii H, Matsuda M, Miura K. Hepatic arterial infusion of interleukin-2 in advanced hepatocellular carcinoma. Acta Oncol. 1993;32:43–51.

    Article  CAS  PubMed  Google Scholar 

  138. Kawai S, Tani M, Okamura J, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1994;33(Suppl):S97–102.

    Google Scholar 

  139. Yoshimi F, Nagao T, Inoue S, et al. Comparison of hepatectomy and transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: necessity for prospective randomized trial. Hepatology. 1992;16:702–6.

    Article  CAS  PubMed  Google Scholar 

  140. Epstein B, Ettinger D, Leichner PK, Order SE. Multimodality cisplatin treatment in nonresectable alpha-fetoprotein-positive hepatoma. Cancer. 1991;67:896–900.

    Article  CAS  PubMed  Google Scholar 

  141. Rougier P, Roche A, Pelletier G, Ducreux M, Pignon JP, Etienne JP. Efficacy of chemoembolization for hepatocellular carcinomas: experience from the Gustave Roussy Institute and the Bicetre Hospital. J Surg Oncol Suppl. 1993;3:94–6.

    Article  CAS  PubMed  Google Scholar 

  142. Onohara S, Kobayashi H, Itoh Y, Shinohara S. Intra-arterial cis-platinum infusion with sodium thiosulfate protection and angiotensin II induced hypertension for treatment of hepatocellular carcinoma. Acta Radiol. 1988;29:197–202.

    Article  CAS  PubMed  Google Scholar 

  143. Kajanti M, Rissanen P, Virkkunen P, Franssila K, Mantyla M. Regional intra-arterial infusion of cisplatin in primary hepatocellular carcinoma. A phase II study. Cancer. 1986;58:2386–8.

    Article  CAS  PubMed  Google Scholar 

  144. Nagasue N, Yukaya H, Okamura J, et al. Intra-arterial administration of epirubicin in the treatment of non-resectable hepatocellular carcinoma. Epirubicin Study Group for Hepatocellular Carcinoma. Gan To Kagaku Ryoho. 1986;13:2786–92.

    CAS  PubMed  Google Scholar 

  145. Lin CP, Yu HC, Cheng JS, et al. Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma. J Chin Med Assoc. 2004;67:602–10.

    PubMed  Google Scholar 

  146. Jang BK, Kwon KM, Chung WJ, et al. Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil and cisplatin. Korean J Hepatol. 2004;10:271–8.

    PubMed  Google Scholar 

  147. Carr BI. Gemcitabine hepatic arterial chemo-embolization in the treatment of hepatocellular carcinoma. Proc ASCO. 2006;24:4141.

    Google Scholar 

  148. Kawai S, Okamura J, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1992;31(Suppl):S1–6.

    Article  PubMed  Google Scholar 

  149. Kawai S, Tani M, Okamura J, et al. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 1997;24:S6-38–45.

    Google Scholar 

  150. Watanabe S, Nishioka M, Ohta Y, Ogawa N, Ito S, Yamamoto Y. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol. 1994;33(Suppl):S93–6.

    Article  PubMed  Google Scholar 

  151. Hatanaka Y, Yamashita Y, Takahashi M, et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology. 1995;195:747–52.

    Article  CAS  PubMed  Google Scholar 

  152. Uchino J, Une Y, Sato Y, Gondo H, Nakajima Y, Sato N. Chemohormonal therapy of unresectable hepatocellular carcinoma. Am J Clin Oncol. 1993;16:206–9.

    Article  CAS  PubMed  Google Scholar 

  153. Madden MV, Krige JE, Bailey S, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut. 1993;34:1598–600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Chung YH, Song IH, Song BC, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer. 2000;88:1986–91.

    Article  CAS  PubMed  Google Scholar 

  155. Yoshikawa M, Saisho H, Ebara M, et al. A randomized trial of intrahepatic arterial infusion of 4′-epidoxorubicin with Lipiodol versus 4′-epidoxorubicin alone in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol. 1994;33(Suppl):S149–52.

    Article  PubMed  Google Scholar 

  156. Kajanti M, Pyrhonen S, Mantyla M, Rissanen P. Intra-arterial and intravenous use of 4′ epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. Am J Clin Oncol. 1992;15:37–40.

    Article  CAS  PubMed  Google Scholar 

  157. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK. Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology. 1999;46:1122–5.

    CAS  PubMed  Google Scholar 

  158. Bhattacharya S, Novell JR, Dusheiko GM, Hilson AJ, Dick R, Hobbs KE. Epirubicin-Lipiodol chemotherapy versus 131iodine-Lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer. 1995;76:2202–10.

    Article  CAS  PubMed  Google Scholar 

  159. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 1998;27:1578–83.

    Article  CAS  PubMed  Google Scholar 

  160. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol. 1998;29:129–34.

    Article  CAS  PubMed  Google Scholar 

  161. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002;224:47–54.

    Article  PubMed  Google Scholar 

  162. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998;352:17–20.

    Google Scholar 

  163. Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology 2004;40:1361–9.

    Google Scholar 

  164. Grimaldi C, Bleiberg H, Gay F, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol. 1998;16:411–7.

    CAS  PubMed  Google Scholar 

  165. Falkson G, Lipsitz S, Borden E, Simson I, Haller D. Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menogaril. Am J Clin Oncol. 1995;18:287–92.

    Article  CAS  PubMed  Google Scholar 

  166. Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology. 2007;45:9–15.

    Article  CAS  PubMed  Google Scholar 

  167. Chao Y, Chan WK, Wang SS, et al. Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997;12:277–81.

    Article  CAS  PubMed  Google Scholar 

  168. Villa E, Ferretti I, Grottola A, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer. 2001;84:881–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  169. Carr BI. Complete suppression of DCP/PIVKA 2 levels by vitamin K1 administration to patients with hepatocellular carcinoma (HCC). Hepatology. 1993;18:500.

    Google Scholar 

  170. Chuah B, Lim R, Boyer M, et al. Multi-centre phase II trial of thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol. 2007;46:234–8.

    Article  CAS  PubMed  Google Scholar 

  171. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2007;110:581–9.

    Article  CAS  PubMed  Google Scholar 

  172. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs. 2007;25:77–84.

    Article  CAS  PubMed  Google Scholar 

  173. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26:2992–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  174. Palmer DH, Midgley RS, Mirza N, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology. 2008;3:3.

    Google Scholar 

  175. Borbath I, Lhommel R, Bittich L, et al. 131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2005;17:905–10.

    Article  CAS  PubMed  Google Scholar 

  176. Order S, Pajak T, Leibel S, et al. A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys. 1991;20:953–63.

    Article  CAS  PubMed  Google Scholar 

  177. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res. 1999;5:1676–81.

    CAS  PubMed  Google Scholar 

  178. Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer. 2002;94:421–7.

    Article  CAS  PubMed  Google Scholar 

  179. Farinati F, De Maria N, Fornasiero A, et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci. 1992;37:659–62.

    Article  CAS  PubMed  Google Scholar 

  180. Liu CL, Fan ST, Ng IO, Lo CM, Poon RT, Wong J. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol. 2000;95:218–22.

    Article  CAS  PubMed  Google Scholar 

  181. Martinez Cerezo FJ, Tomas A, Donoso L, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol. 1994;20:702–6.

    Article  CAS  PubMed  Google Scholar 

  182. Barbare JC, Bouche O, Bonnetain F, et al. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol. 2005;23:4338–46.

    Article  CAS  PubMed  Google Scholar 

  183. Gallo C, De Maio E, Di Maio M, et al. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma. BMC Cancer. 2006;6:196.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  184. Lai CL, Lau JY, Wu PC, et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology. 1993;17:389–94.

    Article  CAS  PubMed  Google Scholar 

  185. Lai CL, Wu PC, Lok AS, et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer. 1989;60:928–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  186. Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000;31:54–8.

    Article  CAS  PubMed  Google Scholar 

  187. Cebon J, Findlay M, Hargreaves C, et al. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer. 2006;95:853–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology. 2002;49:1245–50.

    CAS  PubMed  Google Scholar 

  189. Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, et al. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol. 2007;13:3164–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  190. Rabe C, Pilz T, Allgaier HP, et al. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide. Z Gastroenterol. 2002;40:395–400.

    Article  CAS  PubMed  Google Scholar 

  191. Slijkhuis WA, Stadheim L, Hassoun ZM, et al. Octreotide therapy for advanced hepatocellular carcinoma. J Clin Gastroenterol. 2005;39:333–8.

    Article  CAS  PubMed  Google Scholar 

  192. Verset G, Verslype C, Reynaert H, et al. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br J Cancer. 2007;97:582–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  193. Carr BI. A phase I/phase II study of high-dose vitamin K in patients with advanced, inoperable hepatocellular carcinoma. Proc AASLD Hepatology. 1994;20:727.

    Google Scholar 

  194. Zamibone A, Biasi L, Graffeo M, et al. Phase II study of high-dose vitamin K1 in hepatocellular carcinoma. Proc ASCO. 1998;17:307A.

    Google Scholar 

  195. Lin AY, Brophy N, Fisher GA, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer. 2005;103:119–25.

    Article  CAS  PubMed  Google Scholar 

  196. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol. 2000;23:319–21.

    Article  CAS  PubMed  Google Scholar 

  197. Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 2005;103:749–55.

    Article  CAS  PubMed  Google Scholar 

  198. Pinter M, Wichlas M, Schmid K, et al. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. Eur J Gastroenterol Hepatol. 2008;20:1012–9.

    Article  CAS  PubMed  Google Scholar 

  199. Schwartz JD, Sung M, Schwartz M, et al. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist. 2005;10:718–27.

    Article  CAS  PubMed  Google Scholar 

  200. Yau T, Chan P, Wong H, et al. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma. Oncology. 2007;72(Suppl 1):67–71.

    Article  CAS  PubMed  Google Scholar 

  201. Brans B, Van Laere K, Gemmel F, et al. Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2002;29:928–32.

    Article  CAS  PubMed  Google Scholar 

  202. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet. 1999;353:797–801.

    Article  CAS  PubMed  Google Scholar 

  203. Leung WT, Lau WY, Ho S, et al. Selective internal radiation therapy with intra-arterial iodine-131-Lipiodol in inoperable hepatocellular carcinoma. J Nucl Med. 1994;35:1313–8.

    CAS  PubMed  Google Scholar 

  204. Carr BI, Amesur N, Zajko A, et al. Safety and efficacy of hepatic artery 90Y microspheres in unresectable hepatocellular carcinoma (HCC). Proc ASCO. 2003;22:1046.

    Google Scholar 

  205. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41:1673–81.

    CAS  PubMed  Google Scholar 

  206. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int J Radiat Oncol Biol Phys. 1998;40:583–92.

    Article  CAS  PubMed  Google Scholar 

  207. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13:S223–9.

    Article  PubMed  Google Scholar 

  208. Carr BI. Chemotherapy in diagnosis and treatment of HCC. In Livraghi T, Mukuuchi M, Buscarini L, editors. Greenwich medical; 1997. p 367–391.

    Google Scholar 

  209. Collins J. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984;2:498–504.

    CAS  PubMed  Google Scholar 

  210. Siegel AB, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;26(18):2992–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  211. Zhu AX, et al. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist. 2008;13(2):120–5.

    Article  CAS  PubMed  Google Scholar 

  212. Chia WK, et al. Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma. Ann Acad Med Singapore. 2008;37(7):554–8.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Izmir Biomedicine and Genome Center, Dokuz Eylül University, Izmir, Turkey

    Brian I. Carr

  2. Lusaka Apex Medical University, Lusaka, Zambia

    Brian I. Carr

  3. Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA

    Srikanth Nagalla

  4. GI Malignancies Center‬, Division of Oncology, Tel-Aviv Sourasky Medical Center‬, Tel Aviv, Israel

    Ravit Geva

Authors
  1. Brian I. Carr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Srikanth Nagalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ravit Geva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian I. Carr .

Editor information

Editors and Affiliations

  1. Dokuz Eylul University, Izmir Biomedicine and Genome Center Dokuz Eylul University, Izmir, Izmir, Turkey

    Brian I. Carr

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Carr, B.I., Nagalla, S., Geva, R. (2016). Medical Therapy of HCC. In: Carr, B. (eds) Hepatocellular Carcinoma. Current Clinical Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-34214-6_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-34214-6_33

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-34212-2

  • Online ISBN: 978-3-319-34214-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation